News, Deals & Cases
Recent Financial Market Transactions and Updates.
-
Read more: Sonova’s Issuance of Dual-Tranche Bonds
Sonova’s Issuance of Dual-Tranche Bonds
On 2 May 2022, Sonova Holding AG successfully placed CHF 450 million Bonds. The Bonds are governed by Swiss law and are to be listed on the SIX Swiss Exchange. The Bonds will be issued in two tranches, the first tranche with a duration until 2029 and a coupon of 1.050% and the second tranche…
Reference: CapLaw-2022-21 -
Read more: Zürcher Kantonalbank’s Issuance of Fixed-to-Floating Rate Tier 2 Bonds
Zürcher Kantonalbank’s Issuance of Fixed-to-Floating Rate Tier 2 Bonds
On 13 April 2022, Zürcher Kantonalbank successfully completed its issuance of EUR 500 million 2.020 per cent. Fixed-to-Floating Rate Tier 2 Bonds due 2028. The Bonds are regulatory capital instruments that are eligible to fulfil Zürcher Kantonalbank’s Swiss gone concern requirements.
Reference: CapLaw-2022-22 -
Read more: Bell Food Group’s Issuance of Bonds
Bell Food Group’s Issuance of Bonds
On 11 April 2022 Bell Food Group placed CHF 300 million bonds with a term to maturity of 7 years. The net proceeds will be used to refinance the existing bond that matured on 16 May 2022 as well as for general financing purposes, in particular for the investment programme for Switzerland. With this investment…
Reference: CapLaw-2022-23 -
Read more: Credit Suisse AG’s Registered Offering of Senior Notes
Credit Suisse AG’s Registered Offering of Senior Notes
On 7 April 2022, Credit Suisse AG completed its registered offering of USD 2.5 billion aggregate principal amount of senior notes. The offering consisted of USD 2.1 billion aggregate principal amount of 3.700% senior notes due 2025 and USD 400 million aggregate principal amount of floating rate senior notes due 2025. The notes were issued…
Reference: CapLaw-2022-24 -
Read more: Geberit’s Bond Offering
Geberit’s Bond Offering
On 29 March 2022, Geberit AG completed the issuance and placement of CHF 150 million fixed rate bonds with a term of 5.5 years and a coupon of 0.75%. The Bonds have been admitted to trading and listed on SIX Swiss Exchange.
Reference: CapLaw-2022-25 -
Read more: Credit Suisse Group AG’s Issuance of Bail-inable Notes
Credit Suisse Group AG’s Issuance of Bail-inable Notes
On 24 March 2022, Credit Suisse Group AG successfully completed its issuance of (i) EUR 2 billion aggregate principal amount of 2.125 per cent. Fixed Rate Reset Senior Callable Notes due 2026 and (ii) EUR 1.5 billion aggregate principal amount of 2.875 per cent. Fixed Rate Reset Senior Callable Notes due 2032 under its Medium…
Reference: CapLaw-2022-26 -
Read more: UBS Group AG’s Issuance of EUR 1Fixed Rate/Fixed Rate Senior Notes under its Senior Debt Programme
UBS Group AG’s Issuance of EUR 1Fixed Rate/Fixed Rate Senior Notes under its Senior Debt Programme
On 21 March 2022, UBS Group AG successfully completed its issuance of EUR 1.5 billion in aggregate principal amount of 1.000 per cent. Fixed Rate/Fixed Rate Callable Senior Notes due March 2025 under its Senior Debt Programme. The Notes are bail-inable (TLAC) bonds that are eligible to count towards UBS Group AG’s Swiss gone concern…
Reference: CapLaw-2022-27 -
Read more: Roche’s Issuance of Senior Notes and Bonds
Roche’s Issuance of Senior Notes and Bonds
On 10 March 2022, Roche Holdings, Inc. successfully completed its issuance of USD 5 billion in aggregate principal amount of senior notes, consisting of USD 1.25 billion 1.882% Notes due 2024, USD 1 billion 2.132% Notes due 2025, USD 1,25 billion 2.314% Notes due 2027, USD 750 million Floating Rate Notes due 2023, and USD…
Reference: CapLaw-2022-28 -
Read more: Perfect Holding reverse takeover (RTO) transaction with Kinarus
Perfect Holding reverse takeover (RTO) transaction with Kinarus
On 3 June 2022, Perfect Holding SA (Perfect Holding) announced the successful completion of its reverse takeover (RTO) transaction with Kinarus AG. The SIX Swiss Exchange listed Perfect Holding has acquired more than 95% of the shares of Kinarus, a privately owned clinical-stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment…